HIV Treatment Bulletin - Vol. 6, No. 7, July 2005

On June 22, 2005, the US Food and Drug Administration (FDA) granted accelerated approval of a new protease inhibor, tipranavir (Aptivus). Tipranavir, co-administered with 200 mg of ritonavir, is indicated for adult patients who are highly treatment-experienced or have HIV-1 strains resistant to multiple PIs.

The approval of tipranavir/r is based on 24-week results from of two controlled phase III studies previously reported in HTB (RESIST 1 and 2). A statistically greater percentage of HIV-positive patients taking tipranavir/r achieved treatment response versus the comparator group (40% vs 18%). Treatment response was defined as a confirmed 1 log or greater decrease in HIV RNA from baseline.

The approved dose of tipranavir is 500 mg taken with 200 mg of ritonavir, twice daily with food. Taking the drug with food improves absorption.

Source: FDA listlesrve and Boehringer Ingelheim PR (See, also, Tipranavir News

050710
IB050607-15

©2005. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone / Firestone Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.